NCT02026362View on ClinicalTrials.gov

Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2019

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

MASCT:Multiple Antigens Specific Cellular Therapy

autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .

OTHER

The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment

Trial Locations (1)

518006

JOE ZHOU, Shenzhen

Sponsors

Lead Sponsor

HRYZ Biotech Co.
All Listed Sponsors
collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Beijing 302 Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

lead

HRYZ Biotech Co.

INDUSTRY

NCT02026362 - Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). | Biotech Hunter | Biotech Hunter